THC Delays Progression Of Lou Gehrig’s Disease, Study Says

San Francisco, CA: The administration of the cannabinoid THC in mice delayed disease progression of an animal model of amyotrophic lateral sclerosis (ALS), according to clinical findings published in the journal Amyotrophic Lateral Sclerosis & Other Motor Neuron Disorders. Also known as Lou Gehrig’s disease, ALS is a chronic, often fatal condition marked by a gradual degeneration of the nerve cells in the central nervous system that control voluntary muscle movement.

“Treatment with Delta(9)-tetrahydrocannabinol was effective if administered either before or after onset of [symptoms] in the ALS mouse model,” researchers at the MDA/ALS Center of San Francisco determined. “Administration at the onset of tremors delayed motor impairment and prolonged survival in Delta(9)-THC treated mice when compared to … controls.”

Authors concluded, “As Delta(9)-THC is well tolerated, it and other cannabinoids may prove to be novel therapeutic targets for the treatment of ALS.”

For more information, please contact Paul Armentano, NORML Senior Policy Analyst, at (202) 483-5500.